Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 1412 | 7537 | 47.1 | 92% |
Classes in level above (level 3) |
Classes in level below (level 1) |
| ID, lev. below | Publications | Label for level below |
|---|---|---|
| 4118 | 1768 | JNK//MKK4//JNK3 |
| 5106 | 1603 | RAF//RAF 1//LEO JENKINS CANC |
| 5806 | 1504 | MK2//MAPKAP K2//MK5 |
| 12741 | 821 | MKP 1//MAP KINASE PHOSPHATASE//DUAL SPECIFICITY PHOSPHATASE |
| 14782 | 681 | KSR1//PEA 15//IST ENDOCRINOL ONCOL SPERIMENTALE GAETANO SALVA |
| 16568 | 582 | COFFIN LOWRY SYNDROME//RSK2//SL0101 |
| 22563 | 321 | ERK5//MEK5//EXTRACELLULAR SIGNAL REGULATED KINASE 5 ERK5 |
| 27310 | 191 | TPL2//TPL 2//TPL2 KINASE |
| 34652 | 66 | VRK1//VRK2//EXPT THER EUT TRANSLAT ONCOL PROGRAM |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | COFFIN LOWRY SYNDROME | Author keyword | 80 | 84% | 1% | 43 |
| 2 | ERK5 | Author keyword | 78 | 65% | 1% | 74 |
| 3 | JNK | Author keyword | 62 | 16% | 5% | 366 |
| 4 | MAP KINASE | Author keyword | 39 | 12% | 4% | 316 |
| 5 | P38 | Author keyword | 38 | 15% | 3% | 234 |
| 6 | MKK4 | Author keyword | 37 | 61% | 1% | 39 |
| 7 | VRK1 | Author keyword | 35 | 89% | 0% | 16 |
| 8 | CANC UK ST S PONSE | Address | 34 | 93% | 0% | 13 |
| 9 | JNK3 | Author keyword | 33 | 66% | 0% | 31 |
| 10 | MKP 1 | Author keyword | 33 | 40% | 1% | 65 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | COFFIN LOWRY SYNDROME | 80 | 84% | 1% | 43 | Search COFFIN+LOWRY+SYNDROME | Search COFFIN+LOWRY+SYNDROME |
| 2 | ERK5 | 78 | 65% | 1% | 74 | Search ERK5 | Search ERK5 |
| 3 | JNK | 62 | 16% | 5% | 366 | Search JNK | Search JNK |
| 4 | MAP KINASE | 39 | 12% | 4% | 316 | Search MAP+KINASE | Search MAP+KINASE |
| 5 | P38 | 38 | 15% | 3% | 234 | Search P38 | Search P38 |
| 6 | MKK4 | 37 | 61% | 1% | 39 | Search MKK4 | Search MKK4 |
| 7 | VRK1 | 35 | 89% | 0% | 16 | Search VRK1 | Search VRK1 |
| 8 | JNK3 | 33 | 66% | 0% | 31 | Search JNK3 | Search JNK3 |
| 9 | MKP 1 | 33 | 40% | 1% | 65 | Search MKP+1 | Search MKP+1 |
| 10 | RAF | 30 | 25% | 1% | 105 | Search RAF | Search RAF |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MAP KINASE | 206 | 14% | 19% | 1414 |
| 2 | N TERMINAL KINASE | 106 | 16% | 8% | 597 |
| 3 | JNK | 100 | 24% | 5% | 363 |
| 4 | DUAL SPECIFICITY PHOSPHATASE | 90 | 43% | 2% | 159 |
| 5 | MKP 1 | 68 | 70% | 1% | 57 |
| 6 | MAP KINASES | 62 | 18% | 4% | 322 |
| 7 | SIGNAL TRANSDUCTION PATHWAY | 62 | 15% | 5% | 375 |
| 8 | C JUN | 62 | 10% | 8% | 575 |
| 9 | ERK2 | 60 | 53% | 1% | 80 |
| 10 | ERK3 | 57 | 95% | 0% | 19 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases | 2011 | 346 | 427 | 57% |
| Signal integration by JNK and p38 MAPK pathways in cancer development | 2009 | 635 | 159 | 59% |
| ERK1/2 MAP kinases: Structure, function, and regulation | 2012 | 208 | 249 | 46% |
| Mechanisms and functions of p38 MAPK signalling | 2010 | 293 | 165 | 58% |
| Mitogen-activated protein kinases in innate immunity | 2013 | 106 | 142 | 44% |
| MAMMALIAN MAPK SIGNAL TRANSDUCTION PATHWAYS ACTIVATED BY STRESS AND INFLAMMATION: A 10-YEAR UPDATE | 2012 | 187 | 331 | 48% |
| Dual-specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling | 2013 | 58 | 132 | 75% |
| Differential regulation and properties of MAPKs | 2007 | 603 | 112 | 70% |
| Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions | 2001 | 2170 | 438 | 60% |
| Signal transduction by the JNK group of MAP kinases | 2000 | 2511 | 131 | 50% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CANC UK ST S PONSE | 34 | 93% | 0.2% | 13 |
| 2 | LEO JENKINS CANC | 11 | 29% | 0.4% | 32 |
| 3 | PROGRAM MOL SIGNAL TRANSDUCT | 10 | 46% | 0.2% | 16 |
| 4 | MED STRAHLENKUNDE ZELLFOR | 8 | 23% | 0.4% | 31 |
| 5 | INVITROGEN DISCOVERY SERV | 8 | 100% | 0.1% | 5 |
| 6 | PROGRAM PHARM | 7 | 56% | 0.1% | 9 |
| 7 | ANTIBIOT BIOARCHITECT GRP | 6 | 80% | 0.1% | 4 |
| 8 | SHOCK MICROCIRCULAT PLA | 6 | 58% | 0.1% | 7 |
| 9 | CR UK ST S PONSE | 6 | 100% | 0.1% | 4 |
| 10 | IST ENDOCRINOL ONCOL SPERIMENTALE GAETANO SALVA | 5 | 60% | 0.1% | 6 |
Related classes at same level (level 2) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000022449 | EGR 1//C FOS//CREM |
| 2 | 0.0000018053 | 14 3 3 PROTEINS//14 3 3 SIGMA//14 3 3 |
| 3 | 0.0000014216 | PROTEIN KINASE D//PROTEIN KINASE D PKD//MEF2C |
| 4 | 0.0000013671 | FARNESYLTRANSFERASE//PALMITOYLATION//RLIP76 |
| 5 | 0.0000012826 | CANTHARIDIN//NORCANTHARIDIN//CIP2A |
| 6 | 0.0000012659 | PTP1B//PROTEIN TYROSINE PHOSPHATASE//PRL 3 |
| 7 | 0.0000011626 | I KAPPA B//C REL//IKK |
| 8 | 0.0000011150 | HIPPO PATHWAY//YAP//HIPPO |
| 9 | 0.0000010272 | SERUM RESPONSE FACTOR//MYOCARDIN//KLF4 |
| 10 | 0.0000010162 | RKIP//RAF KINASE INHIBITOR PROTEIN//HIPPOCAMPAL CHOLINERGIC NEUROSTIMULATING PEPTIDE |